Objective: The aim of study was to fi nd predictive factors for treatment failure of the continuous positive airway pressure (CPAP). Background: Sleep apnea syndrome (SAS) affects 4-8 % of the general population. Despite good adherence, CPAP is ineffective in about 13 % of patients. In those patients, a higher level of treatment by bilevel positive airway pressure (BiPAP) has to be used. Methods: Totally, 983 patients with moderate to severe SAS (AHI ≥ 15, apnea/hypopnea index) were treated with CPAP during 2005-2010 in a tertiary hospital. 506 patients fulfi lled the inclusion criteria. In all patients, sleep monitoring was performed and AHI, the presence of hyposaturation T90 (oxygen saturation less than 90 %) and ODI (oxygen distress index) were recorded and a comparison was made between CPAP-effective and CPAP-failure treatment groups. Results: Of all the variables evaluated, only T90 signifi cantly predicted the failure of CPAP treatment. A T90 value above 43.5 % predicted CPAP failure in 94.5 % of patients regardless of age. Conclusions: The value of T90 enables the determination of patients who will not benefi t from CPAP treatment and BiPAP should be used as a treatment of the fi rst choice (Tab. 2, Fig. 1 
Sleep-disordered breathing affects approximately 15 % of the population (1) . According to epidemiological studies, more than half are sleep apnea syndrome (SAS) whose diagnosis requires sleep monitoring, an ear-nose-throat examination (ENT) of the upper respiratory tract and a determination of treatment options (2, 3, 4) .
With increasing age, the proportion of the obstructive form of SAS (OSAS) increase, affecting up to 80 % of patients, with central and mixed forms of SAS accounting for 10 % each (5, 6).
Breathing disorders during sleep are accompanied by severe cardiovascular complications (7). Typically, no physiological decrease in systolic and diastolic blood pressure (non-dipper) occurs during night sleep due to the presence of apneic pauses. Sleep apnea syndrome is a risk factor for adverse cardiovascular events such as myocardial infarction, heart failure and stroke occurring 3 times more frequently in SAS patients (8, 9). In patients with untreated SAS, atrial fi brillation is more common and reoccurs frequently even after successful cardioversion. Similarly, in diabetic patients glycaemic control could be diffi cult to achieve without treatment of SAS. Central nervous system symptoms, such as excessive daytime sleepiness (10) are the main clinical symptom severely limiting in everyday life activities leading to disability in some patients. In older patients with SAS, memory problems and depression are common and further worsen the quality of life (11, 12) .
While in milder forms of SAS a surgical treatment is preferred, for patients with moderate to severe SAS, positive airway pressure (PAP) therapy is primarily indicated (13, 14) . The fi rst treatment choice is a single-level device with continuous positive pressure CPAP (15) . Before treatment it is necessary to carefully choose the mask and determine the correct therapeutic pressure applied to prevent all adverse breathing events (16, 17) . If CPAP fails, bi-level positive airway pressure (BiPAP) is the next step of treatment. Surgical treatment is an option depending on specifi c situations where the effect of PAP is limited by the obstruction of the upper airways (16, 17, 18) or when conservative therapy for severe obstructive SAS fails (19, 20, 21, 22, 23) .
Approximately 13 % of patients with good adherence to CPAP treatment experience treatment failure (24, 25). In these patients, CPAP prevents apneic pauses, but doesn't resolve the problem of hypoventilation. Residual AHI may be normal, but hyposaturation persists. Until now, only one study has dealt with this problem, however it did not evaluate clear factors predicting successful treatment with CPAP.
The aim of our study was to compare selected characteristics of SAS in two groups of patients (groups with successful and unsuccessful treatment) to identify patients who will benefi t from CPAP treatment, and those for whom a higher type of treatment such as BiPAP is primarily indicated (26, 27).
Patients and methods

Patients
Between 2005-2010, totally 983 patients were treated for SAS in the Faculty Hospital in the city of Pilsen, Czech Republic. The studied sample consisted of 506 consecutive patients who fulfi lled the inclusion criteria: 367 males (73 %) and 139 females (27 %) with the mean age of 58.91 ± 10.2 year. A retrospective analysis of the patients' charts was carried out. Table 1 summarizes characteristics of the patients' sample.
Study sample characteristics
Ethics
The Ethics Committee of the Faculty Hospital Pilsen granted approval of data analyses.
Methods
Inclusion criteria: an OSAS diagnosis determined by an ENT specialist and/or pneumologist, AHI ≥ 15, diagnostic and control evaluation performed with the same polygraphic monitoring systems (Miniscreen 8, Vitaloc, Stardust), the use of CPAP devices as the fi rst choice of therapy, good adherence to the treatment by the patient.
Exclusion criteria: previous treatment of SAS including surgery, COPD, alcohol abuse.
The patient sample was divided into the two groups: successful treatment (group I) and unsuccessful treatment (group II). In all patients, the main polygraphic characteristics were recorded and the effectiveness of CPAP was evaluated. The differences in the observed parameters between the treatment group I and group II were analyzed. Additionally, we analyzed the infl uence of age on treatment success.
The following variables were recorded: • The AHI (apnea-hypopnea index) was defi ned as the total number of apnea and hypopnea during one hour.
• The AI (apnea index) was defi ned as the total number of apnea during one hour.
• The ODI (oxygen distress index) was defi ned as the average desaturation per hour of sleep.
• Average saturation was defi ned as the mean SaO 2 during sleep.
• T90 was defi ned by the percentage of sleep time below 90 % SaO 2 .
• Mild SAS was defi ned as AHI 5-14.9 • Moderate SAS was defi ned as AHI 15-29.9 • Severe SAS was defi ned as AHI 30 and more.
• The effect of CPAP was assessed after 3 months of treatment.
• Treatment failure was defi ned as: A) AHI > 10 and lower than 75 % decrease of baseline AHI value; B) AHI < 10 but persisting hyposaturation, T90 ≥ 10 % and ODI ≥ 10.
Statistical methods
For the statistical evaluation, we used the standard methods for testing hypotheses concerning the agreement of variance and mean values with a signifi cance level of 0.05 and 0.01. The most appropriate method was the discriminating method "minimum distance to type value" of the given class. The threshold value for the parameter T90 was determined empirically to provide the best possible discriminating features (28). When examining the values of AHI, AI and ODI parameters a direct correlation and relation to the successfulness of CPAP treatment cannot be established.
Results
CPAP treatment effect
When examining the variance of SaO 2 and the mean value of SaO 2 , the parameter was mathematically possible as a discrepancy criterion between both groups, nonetheless not advantageous for practical use for a low variance of values.
Through T90 analysis (Fig. 1) we found that the mean values did not match, and in these two groups, they differed signifi cantly. T90 was a very good indicator in cases of CPAP failure.
Based on the threshold value of 43.5 for the T90 parameter, successful treatment was predicted in 94.5 % of cases.
When examining the age differences, the mean values did not statistically differ between both groups. Thus, CPAP treatment failure did not seem to be infl uenced by age and was not more likely in older patients.
Discussion
The number of patients with SAS is high and as medical care continues to improve, the number of patients diagnosed and treated for SAS will increase. The medical and socio-economic impact on untreated or poorly treated patients is so serious that it warrants proper diagnosis and treatment.
Sleep apnea syndrome is a disabling condition in all ages, as there is more vulnerability to adverse cardiovascular events and disability. Considering that at higher ages there is a special emphasis put on minimally invasive and conservative procedures, the possibility of a simple prediction of success is essential. However, only a few authors evaluated factors contributing to treatment failure.
Repeating critical information improves the patient's adherence to treatment and contributes to better problem solving during SAS treatment. Particularly in elderly patients, communication plays a critical role (29, 30). It shows the interdisciplinary and complex nature of SAS. In our centre, patients profi t from stepwise information consisting of the educational fi lm, interview with a nurse and fi nally, by a doctor.
In this study, 13 % of patients did not achieve satisfactory results after 3 months of CPAP treatment and patients had to switch to the BiPAP type of ventilation. Comparable results were published by Schäfer in a smaller sample of 146 patients (31). Unfortunately, this topic is not dealt with in other literature. We confi rmed the results on a larger and unselected (representative) sample of patients at the University hospital.
We are aware that a retrospective single centre study may limit a generalization of our results. However, the large number of patients and demographic distribution support our fi ndings (2) . At the time, a prospective multi-centre study is being carried out to verify our results.
For parameters AHI, AI, ODI, no relationship to the treatment effect was found. Despite the fact that SaO2 showed a direct mathematical relationship to treatment failure, its utility in clinical practice is limited. The surprising fact was that CPAP treatment failure did not show a relationship to the age of the patient and thus, older patients have the same chance of successful CPAP treatment as younger patients.
The only clinically useful variable is T90, for which we computed a cut off value of 43.5. Patients with T90 of 43.5 or less had a 94.3 % probability of successful CPAP therapy. This marker is commonly used in classical everyday work in centers of sleep medicine and offers us a cheap and practical possibility to choose the right type of treatment for each patient in the fi rst step of therapy. 
